Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
KOREA E & EX

Events

18 Feb 2016 - 20 Feb 2016
24 Feb 2016 - 26 Feb 2016

New Injection Device Approved for Methotrexate

By HospiMedica International staff writers
Posted on 31 Oct 2013
Print article
Image: The Otrexup self-injector in 10 mg formulation (Photo courtesy of Antares Pharma).
Image: The Otrexup self-injector in 10 mg formulation (Photo courtesy of Antares Pharma).
A self-injection device for the subcutaneous administration of methotrexate (MTX) facilitates drug delivery for arthritis sufferers.

The Otrexup self-injector is intended for use by adults with active, severe rheumatoid arthritis (RA) or psoriasis who have not responded to or been able to tolerate first line therapy, as well as for children with active polyarticular juvenile idiopathic arthritis. The device is not indicated for use in children with psoriasis, nor should it be used by pregnant women. And while MTX is also used in the treatment of cancer, Otrexup is not indicated for that use.

Methotrexate is considered a disease-modifying antirheumatic drug (DMARD), effective in relieving joint inflammation and pain, slowing disease progression, and preventing disability by delaying joint destruction. People with RA may be more likely to continue treatment with MTX than with other DMARDs, with more than 50% of people who take MTX for RA continuing to take the medicine for more than three years, longer than any other DMARD. The Otrexup self-injector is a product of Antares Pharma (Ewing, NJ, USA), and has been approved by the US Food and Drug Administration (FDA).

“We are very pleased to receive approval from the FDA for Otrexup because we believe it is an important step up in the standard of care for people living with rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, and psoriasis,” said Paul Wotton, PhD, president and CEO of Antares Pharma.

“The availability of an easy and safe way to administer subcutaneous methotrexate may overcome some of the current barriers to parenteral administration, which could enable more patients to realize the possibility of continued disease control and therefore benefit from subcutaneous methotrexate,” commented Michael Schiff, MD, of the University of Colorado (Denver, USA).

MTX is a cornerstone of therapy for RA and psoriasis, usually given orally once a week, but a substantial number of patients do not respond adequately or cannot tolerate the side effects of the drug, such as nausea, abdominal pain, and dyspepsia. Those patients can be given methotrexate with subcutaneous injections, which can increase the drug's bioavailability, but injection can also pose problems for patients who are afraid of needles or do not have enough manual dexterity remaining to manage needles, syringes, and vials.

Related Links:

Antares Pharma



Print article
LevMed LTD.

Channels

Surgical Techniques

view channel

Nerve Cap Facilitates Management of Symptomatic Neuromas

An innovative device reduces painful neuroma formation, facilitating tissue repair and regeneration following nerve resection. Neurocap is a transparent tubular bioresorbable polymer cap that serves as a synthetic nerve covering. It was designed to help treat symptomatic neuromas by isolating the nerve stump from surrounding... Read more

Women's Health

view channel
Image: The Eclipse vaginal insert in deflated (L) and Inflated (R) states (Phoyo courtesy of Pelvalon).

Vaginal Insert Offers Alternative Treatment for Fecal Incontinence

A novel vaginal insert for bowel control eliminates the need for surgery or an in-office procedure for the treatment of female fecal incontinence (FI). The second-generation Eclipse System is comprised... Read more

Health IT

view channel
Image: The sweat sensor in a prototype flexible plastic wristband (Photo courtesy of Wei Gao et al., Nature).

Wearable Sensor Could Monitor Dehydration and Fatigue

A fully integrated electronic system that can continuously monitor multiple sweat chemicals could be incorporated into wristbands and headbands, according to a new study. The prototype device, developed... Read more

Hospital News

view channel

Geneia Partners with Hospitals on Population Health Training

Geneia (Harrisburg, PA, USA) will provide population health management training to members of the Illinois Health and Hospital Association (IHA; Chicago, USA). Through its education arm, The Geneia Institute, skills-based population health management programs will be delivered to IHA's 209 hospital and nearly 50 health... Read more

Business

view channel

Sentry Data Systems Buys Agilum Healthcare

Sentry Data Systems (Deerfield Beach, FL, USA), a provider of technology solutions for healthcare organizations, has completed the acquisition of Agilum Healthcare Intelligence (Brentwood, TN, USA). The acquisition is intended to add new capabilities to Sentry's current software-as-a-service (SaaS) DataNext healthcare... Read more
Copyright © 2000-2016 Globetech Media. All rights reserved.